JP2023539949A5 - - Google Patents
Info
- Publication number
- JP2023539949A5 JP2023539949A5 JP2023537444A JP2023537444A JP2023539949A5 JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5 JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5
- Authority
- JP
- Japan
- Prior art keywords
- chemical compound
- compound according
- atom
- group
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073104P | 2020-09-01 | 2020-09-01 | |
| US63/073,104 | 2020-09-01 | ||
| PCT/CA2021/051209 WO2022047579A1 (en) | 2020-09-01 | 2021-09-01 | Halogenated psilocybin derivatives and methods of using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539949A JP2023539949A (ja) | 2023-09-20 |
| JP2023539949A5 true JP2023539949A5 (cg-RX-API-DMAC10.html) | 2024-09-09 |
Family
ID=80492287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537444A Pending JP2023539949A (ja) | 2020-09-01 | 2021-09-01 | ハロゲン化シロシビン誘導体および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11998557B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4208445A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023539949A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230062595A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116348106A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021337466A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3191102A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL301026A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023002557A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022047579A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024178504A1 (en) * | 2023-02-27 | 2024-09-06 | Enveric Biosciences Canada Inc. | Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using |
| CN116904348B (zh) * | 2023-06-15 | 2026-07-31 | 厦门大学 | 一种海洋链霉菌Streptomyces sp. P-10及其的应用 |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| GB202315025D0 (en) * | 2023-09-29 | 2023-11-15 | Psylink Uab | Production and medical use of psilocybin and related compounds |
| WO2025073360A1 (en) | 2023-10-04 | 2025-04-10 | Enzyan Biocatalysis Gmbh | Biocatalytic cascade for the production of tryptamine derivatives |
| WO2025189271A1 (en) * | 2024-03-15 | 2025-09-18 | Enveric Biosciences Canada Inc. | N-heterocycle substituted tryptamine derivatives and methods of using |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255199B (it) * | 1992-07-01 | 1995-10-20 | Franco Fraschini | Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani |
| JPH09510216A (ja) * | 1994-03-11 | 1997-10-14 | イーライ・リリー・アンド・カンパニー | 5−ht▲下2b▼受容体に関連する病態を治療するための方法 |
| US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| JP2003516749A (ja) * | 1999-12-15 | 2003-05-20 | シンジェンタ・パティシペーションズ・アクチェンゲゼルシャフト | ハロゲン化反応のための組成物および方法 |
| BR0312175A (pt) | 2002-06-21 | 2005-04-05 | Suven Life Sciences Ltd | Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso |
| WO2004085392A1 (en) * | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| US20080171779A1 (en) * | 2007-01-16 | 2008-07-17 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
| EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| EP3519816A4 (en) * | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2018106907A1 (en) * | 2016-12-08 | 2018-06-14 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary |
| US11723894B2 (en) | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| JP7093961B2 (ja) * | 2018-02-13 | 2022-07-01 | 国立大学法人金沢大学 | ストレス低減薬剤 |
| JP2021514682A (ja) * | 2018-03-08 | 2021-06-17 | ニュー アトラス バイオテクノロジーズ エルエルシー | トリプタミンの生産方法 |
| FI129102B (en) * | 2018-03-19 | 2021-07-15 | Teknologian Tutkimuskeskus Vtt Oy | Heterological production of psilosybin |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| EP3999182A1 (en) * | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| US20230021957A1 (en) * | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| EP4208457A1 (en) | 2020-09-04 | 2023-07-12 | Gilgamesh Pharmaceuticals, Inc. | Azetidinyl tryptamines and methods of treating psychiatric disorders |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
-
2021
- 2021-09-01 MX MX2023002557A patent/MX2023002557A/es unknown
- 2021-09-01 JP JP2023537444A patent/JP2023539949A/ja active Pending
- 2021-09-01 CN CN202180067808.XA patent/CN116348106A/zh active Pending
- 2021-09-01 IL IL301026A patent/IL301026A/en unknown
- 2021-09-01 EP EP21863150.5A patent/EP4208445A4/en active Pending
- 2021-09-01 WO PCT/CA2021/051209 patent/WO2022047579A1/en not_active Ceased
- 2021-09-01 AU AU2021337466A patent/AU2021337466A1/en active Pending
- 2021-09-01 CA CA3191102A patent/CA3191102A1/en active Pending
- 2021-09-01 KR KR1020237010996A patent/KR20230062595A/ko active Pending
-
2022
- 2022-09-06 US US17/903,080 patent/US11998557B2/en active Active
-
2024
- 2024-05-06 US US18/655,793 patent/US12138276B2/en active Active
- 2024-10-08 US US18/909,368 patent/US20250057861A1/en active Pending